Oral Session 3-10A MM: Clinical trials

[OS3-10A-5] KEYNOTE183: Randomized phase 3 study of pembrolizumab/pom/dex in RRMM (including JPN subset)

Kenshi Suzuki¹, Morio Matsumoto², Takaaki Cho³, Junya Kuroda⁴, Masafumi Taniwaki⁴, Kazutaka Sunami⁵, Hiroshi Kosugi⁶, Kiyoshi Ando⁷, Dai Maruyama⁸, Kensei Tobinai⁸, Shinsuke Iida⁹ (1.Japanese Red Cross Medical Center, Tokyo, Japan, 2.NHO Shibukawa Medical Center, Gunma, Japan, 3.Niigata Cancer Center Hospital, Niigata, Japan, 4.Kyoto Prefectural University of Medicine, Kyoto, Japan, 5.NHO Okayama Medical Center, 6.Ogaki Municipal Hospital, Gifu, Japan, 7.Tokai University Hospital, Kanagawa, Japan, 8.National Cancer Center Hospital, Tokyo, Japan, 9.Nagoya City University Hospital, Aichi, Japan)